Compare ABVC & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABVC | RNAZ |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7M | 27.9M |
| IPO Year | 2009 | 2021 |
| Metric | ABVC | RNAZ |
|---|---|---|
| Price | $0.91 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.1K | 18.6K |
| Earning Date | 11-10-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $509,589.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $171.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $1.29 |
| 52 Week High | $2.94 | $12.60 |
| Indicator | ABVC | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 35.10 |
| Support Level | $0.92 | N/A |
| Resistance Level | $1.12 | $1.93 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 51.81 | 13.49 |
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.